Newman DJ, Cragg GM. Pure Merchandise as Sources of New Medicine from 1981 to 2014. J Nat Prod. 2016;79:629–61.
Klevens RM, Morrison MA, Nadle J, Petit S, Gershman Okay, Ray, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Energetic Bacterial Core surveillance (ABCs) MRSA I.S. Invasive methicillin-resistant Staphylococcus aureus infections in the US. Jama-J Am Med Assoc. 2007;298:1763–71.
Rasigade JP, Dumitrescu O, Lina G. New epidemiology of Staphylococcus aureus infections. Clin Microbiol Infec. 2014;20:587–8.
Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Medical Manifestations, and Administration. Clin Microbiol Rev. 2015;28:603–61.
Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati, Holland TL, Fowler VGM. Methicillin-resistant Staphylococcus aureus: an summary of primary and scientific analysis. Nat Rev Microbiol. 2019;17:203–18.
Kourtis AP, Hatfield Okay, Baggs J, Mu Y, See I, Epson, Nadle J, Kainer MA, Dumyati G, Petit S, Ray SM, Ham D, Capers C, Ewing H, Coffin N, McDonald LC, Jernigan J, Cardo DE. Important Indicators: Epidemiology and Latest Tendencies in Methicillin-Resistant and in Methicillin-Prone Staphylococcus aureus Bloodstream Infections – United States. Mmwr-Morb Mortal W. 2019;68:214–9.
Jevons MP, Rolinson GN, Knox R. Celbenin-Resistant Staphylococci. Brit Med J. 1961;1:124–5.
Meawed TE, Ahmed SM, Mowafy SMS, Samir GM, Anis RH. Bacterial and fungal ventilator related pneumonia in critically in poor health COVID-19 sufferers through the second wave. J Infect Public Heal. 2021;14:1375–80.
Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzone B, Codda G, Crea F, De Maria A, Dentone C, Di Biagio A, Icardi G, Magnasco L, Marchese A, Mikulska M, Orsi A, Patroniti N, Robba C, Signori A, Taramasso L, Vena A, Pelosi P, Bassetti M. Bloodstream infections in critically in poor health sufferers with COVID-19. Eur J Clin Make investments. 2020;50:e13319.
Sturm LK, Saake Okay, Roberts PB, Masoudi FA, Fakih MG. Influence of COVID-19 pandemic on hospital onset bloodstream infections (HOBSI) at a big well being system. Am J Infect Management. 2022;50:245–9.
Rothe Okay, Lahmer T, Rasch S, Schneider J, Spinner CD, Wallnöfer F, Wurst M, Schmid RM, Waschulzik B, Fuest Okay, Kriescher S, Schneider G, Busch DH, Feihl S, Heim MF. Dexamethasone remedy and charges of secondary pulmonary and bloodstream infections in critically in poor health COVID-19 sufferers. Multidiscip Respir Med. 2021;16:793.
Hiramatsu Okay, Kayayama Y, Matsuo M, Aiba Y, Saito M, Hishinuma, Iwamoto AT. Vancomycin-intermediate resistance in Staphylococcus aureus. J Glob Antimicrob Re. 2014;2:213–24.
Crits-Christoph A, Diamond S, Butterfield CN, Thomas BC, Banfield JF. Novel soil micro organism possess numerous genes for secondary metabolite biosynthesis. Nature. 2018;558:440–4.
Charlop-Powers Z, Owen JG, Reddy BVB, Ternei MA, Brady SF. Chemical-biogeographic survey of secondary metabolism in soil. Proc Natl Acad Sci USA. 2014;111:3757–62.
Gans J, Wolinsky M, Dunbar J. Computational enhancements reveal nice bacterial range and excessive steel toxicity in soil. Science. 2005;309:1387–90.
Takahashi Y, Omura S. Isolation of recent actinomycete strains for the screening of recent bioactive compounds. J Gen Appl Microbiol. 2003;49:141–54.
Hatano M, Kinoshita N, Igarashi M, Nomoto A. Actinocrispum wychmicini gen. nov., sp nov., a novel member of the household Pseudonocardiaceae, remoted from soil. Int J Syst Evol Micr. 2016;66:4779–84.
Tamaoki T, Kasai M, Shirahata Okay, Ohkubo S, Morimoto M, Mineura Okay, Ishii S, Tomita F. Tetrocarcin, novel antitumor antibiotics II. Isolation, characterization and antitumor exercise. J Antibiot. 1980;33:946–50.
Mallams AK, Puar MS, Rossman RR. Kijanimicin 2. Construction and absolute stereochemistry of Kijanimicin. J Am Chem Soc. 1981;103:3940–3.
Tomita F, Tamaoki T, Shirahata Okay, Kasai M, Morimoto M, Ohkubo, Mineura Okay, Ishii SS. Novel antitumor antibiotics, tetrocarcins. J Antibiot. 1980;33:668–70.
Waitz JA, Horan AC, Kalyanpur M, Lee BK, Loebenberg D, Marquez, Miller G, Patel MGJA. Kijanimicin (Sch 25663), a novel antibiotic produced by Actinomadura kijaniata SCC 1256. Fermentation, isolation, characterization and organic properties. J Antibiot. 1981;34:1101–6.
Tanaka Y, Sato I, Iwai C, Kosaka T, Ikeda T, Nakamura T. Identification of human liver diacetyl reductases by nano-liquid chromatography/Fourier remodel ion cyclotron resonance mass spectrometry. JP2001238692 A. 2001;293:157–68.
Ashton RJ, Kenig MD, Luk Okay, Planterose DN, Scott-Wooden G. MM 46115, a brand new antiviral antibiotic from Actinomadura pelletieri. Traits of the manufacturing cultures, fermentation, isolation, physico-chemical and organic properties. J Antibiot. 1990;43:1387–93.
Tsunakawa M, Tenmyo O, Tomita Okay, Naruse N, Kotake C, Miyaki T, Konishi M, Oki TT. Quartromicin, a posh of novel antiviral antibiotics. I. Manufacturing, isolation, physico-chemical properties and antiviral exercise. J Antibiot. 1992;45:180–8.
Kawashima A, Nakamura Y, Ohta Y, Akama T, Yamagishi M, Hanada Okay. New ldl cholesterol biosynthesis inhibitors MC-031 (O-demethylchlorothricin), -032 (O-demethylhydroxychlorothricin), -033 and -034. J Antibiot. 1992;45:207–12.
Riedlinger J, Reicke A, Zahner H, Krismer B, Bull AT, Maldonado, WARD AC, Goodfellow M, Bister B, Bischoff D, Sussmuth RD, Fiedler HPLA. Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by the marine Verrucosispora pressure AB-18-032. J Antibiot. 2004;57:271–9.
Jiang ZD, Jensen PR, Fenical W. Lobophorins A and B, new antiinflammatory macrolides produced by a tropical marine bacterium. Bioorg Med Chem Lett. 1999;9:2003–6.
Ohtsuka T, Kotaki H, Nakayama N, Itezono Y, Shimma N, Kudoh T, Kuwahara T, Arisawa M, Yokose Okay, Seto HT. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489. II. Isolation, characterization and organic actions. J Antibiot. 1993;46:11–7.
